# SYMPHONY-1 (NCT04224493)

> A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

No report yet. It can be ordered.

- Drugs tested: tazemetostat
- Indication: relapsed/refractory follicular lymphoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04224493
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Epizyme, Inc.
- Conditions: Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma
- Interventions: Tazemetostat; Tazemetostat; Placebo oral tablet; Lenalidomide; Rituximab
- Enrollment: 599
- Primary outcome: Phase 1b: Recommended Phase 3 Dose (RP3D) of tazemetostat in combination with rituximab and lenalidomide (R2)
- Primary outcome: Phase 3: Progression-Free Survival (PFS) in the Intent-to-treat wild-type (ITT-WT) populations
- Primary outcome: Phase 3: PFS in the Intent-to-treat mutant-type (ITT-MT) population
- Primary outcome: Phase 3: PFS in the R/R FL population regardless of mutation status by Investigator assessment
- Primary outcome: Phase 3: Progression-Free Survival (PFS) in the all comer (ITT-All) populations.

## Indexed commentary on SYMPHONY-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- Podcasts: 6
- X threads: 4
- YouTube: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=symphony-1-nct04224493

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04224493", "email": "<work email>"}; the inbox owner confirms by the emailed link.